These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

887 related items for PubMed ID: 14500805

  • 1. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM.
    N Engl J Med; 2003 Sep 25; 349(13):1216-26. PubMed ID: 14500805
    [Abstract] [Full Text] [Related]

  • 2. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators.
    N Engl J Med; 2003 Sep 25; 349(13):1207-15. PubMed ID: 14500804
    [Abstract] [Full Text] [Related]

  • 3. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ, PaTH Study Investigators.
    N Engl J Med; 2005 Aug 11; 353(6):555-65. PubMed ID: 16093464
    [Abstract] [Full Text] [Related]

  • 4. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.
    N Engl J Med; 2007 Nov 15; 357(20):2028-39. PubMed ID: 18003959
    [Abstract] [Full Text] [Related]

  • 5. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
    Finkelstein JS, Wyland JJ, Lee H, Neer RM.
    J Clin Endocrinol Metab; 2010 Apr 15; 95(4):1838-45. PubMed ID: 20164296
    [Abstract] [Full Text] [Related]

  • 6. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul 15; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 7. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
    N Engl J Med; 2001 May 10; 344(19):1434-41. PubMed ID: 11346808
    [Abstract] [Full Text] [Related]

  • 8. Alendronate for the treatment of osteoporosis in men.
    Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A.
    N Engl J Med; 2000 Aug 31; 343(9):604-10. PubMed ID: 10979796
    [Abstract] [Full Text] [Related]

  • 9. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May 31; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.
    J Clin Endocrinol Metab; 2000 Jun 31; 85(6):2129-34. PubMed ID: 10852440
    [Abstract] [Full Text] [Related]

  • 11. Daily and cyclic parathyroid hormone in women receiving alendronate.
    Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R.
    N Engl J Med; 2005 Aug 11; 353(6):566-75. PubMed ID: 16093465
    [Abstract] [Full Text] [Related]

  • 12. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.
    Bone; 2010 Apr 11; 46(4):935-9. PubMed ID: 20060081
    [Abstract] [Full Text] [Related]

  • 13. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.
    J Clin Endocrinol Metab; 2009 Oct 11; 94(10):3772-80. PubMed ID: 19584192
    [Abstract] [Full Text] [Related]

  • 14. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB.
    J Clin Endocrinol Metab; 2002 Oct 11; 87(10):4528-35. PubMed ID: 12364430
    [Abstract] [Full Text] [Related]

  • 15. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 11; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 16. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
    Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA.
    J Bone Miner Res; 2003 Jan 11; 18(1):9-17. PubMed ID: 12510800
    [Abstract] [Full Text] [Related]

  • 17. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.
    Arthritis Rheum; 2009 Nov 11; 60(11):3346-55. PubMed ID: 19877063
    [Abstract] [Full Text] [Related]

  • 18. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S.
    J Bone Miner Res; 2001 Jan 11; 16(1):113-9. PubMed ID: 11149474
    [Abstract] [Full Text] [Related]

  • 19. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
    Hejdova M, Palicka V, Kucera Z, Vlcek J.
    Pharm World Sci; 2005 Jun 11; 27(3):149-53. PubMed ID: 16096879
    [Abstract] [Full Text] [Related]

  • 20. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 11; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.